RecruitingNot ApplicableNCT02178163

Comprehensive Genomic Analysis in Tissue Samples From Patients With Recurrent or Stage IV Non-small Cell Lung Cancer

A Study to Assess the Ability to Initiate Therapy in Advanced Non-small Cell Lung Cancer (NSCLC) Patients Based on Genomic Analyses of Tumor Specimens.

Sponsor

Barbara Ann Karmanos Cancer Institute

Enrollment

1,020 participants

Start Date

Aug 1, 2014

Study Type

INTERVENTIONAL

Conditions

Stage IV Non-Small Cell Lung Cancer Recurrent Non-small Cell Lung Cancer

Summary

This research trial studies comprehensive genomic analysis in tissue samples from patients with non-small cell lung cancer that has come back or is stage IV. Comprehensive genomic analysis may identify specific gene mutations (changes in deoxyribonucleic acid \[DNA\]) and help doctors to tailor treatment to target the specific mutations.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This study is performing detailed genetic analysis on tumor tissue from patients with advanced or relapsed non-small cell lung cancer (NSCLC), to map the full landscape of genetic mutations driving each person's cancer and help guide future treatment decisions. **You may be eligible if...** - You have stage IV or recurrent non-small cell lung cancer - You have tumor tissue available (either existing archived tissue or are willing to have a new biopsy) - Your blood counts and organ function meet minimum requirements - Your life expectancy is at least 3 months - You are well enough to carry out basic activities (Zubrod performance status 0–2) **You may NOT be eligible if...** - Your tumor tissue is unavailable and you are unwilling to undergo a biopsy - Your organ function (liver, kidneys) does not meet the minimum thresholds - You are unable to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

OTHERcytology specimen collection procedure

Correlative studies

OTHERlaboratory biomarker analysis

Correlative studies

Locations(11)

KCI at McLaren Bay Region

Bay City, Michigan, United States

KCI at Mclaren Bloomfield Hills

Bloomfield Hills, Michigan, United States

KCI At McLaren Clarkston

Clarkston, Michigan, United States

Barbara Ann Karmanos Cancer Institute

Detroit, Michigan, United States

KCI at McLaren Flint

Flint, Michigan, United States

KCI at McLaren Greater Lansing, Mid Michigan Physicians

Lansing, Michigan, United States

KCI at McLaren Lapeer Region

Lapeer, Michigan, United States

KCI at McLaren Macomb

Mount Clemens, Michigan, United States

KCI at McLaren Central Michigan

Mount Pleasant, Michigan, United States

KCI at Northern Michigan

Petoskey, Michigan, United States

KCI at McLaren Port Huron

Port Huron, Michigan, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT02178163

Related Trials

Clinical Trial of CD40L-Augmented TIL for Patients With EGFR, ALK, ROS1 or HER2-Driven NSCLC

NCT056817801 location

Beating Lung Cancer in Ohio Protocol in Improving Survival in Patients With Stage IV Non-Small Cell Lung Cancer

NCT031996511 location

Patient-centered, Optimal Integration of Survivorship and Palliative Care

NCT049009351 location

PALACE: Cemiplimab Trial According to ctDNA Levels

NCT0691757320 locations

Analysis of Circulating Tumor DNA Dynamics to Predict and Monitor Response to TKI in Patients With Advanced NSCLC.

NCT061674601 location